{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-057337","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2025-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.998995+00:00","generated_at":"2026-05-23T08:11:31.499438+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Viking Q1 net loss $45.6M ($0.41/sh); cash $852M; VK2735 Phase 3 expected 2Q25","bullets":["Net loss of $45.6M ($0.41 per share) vs $27.4M ($0.26) in Q1 2024; R&D expense rose to $41.4M.","Cash, cash equivalents & short-term investments totaled $852M at March 31, 2025, down from $903M at Dec 31, 2024.","Phase 3 trials for subcutaneous VK2735 in obesity expected to begin in 2Q25; Phase 2 VENTURE-Oral Dosing trial fully enrolled, data expected 2H25.","Signed broad manufacturing agreement with CordenPharma for VK2735 API and fill/finish capacity; prepayments from 2025-2028 credited against future orders.","Dual amylin/calcitonin receptor agonist (DACRA) program IND planned for 2H25."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-057337","json":"https://secwatch.observer/filing/0000950170-25-057337.json","markdown":"https://secwatch.observer/filing/0000950170-25-057337.md","text":"https://secwatch.observer/filing/0000950170-25-057337.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025057337/0000950170-25-057337-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025057337/vktx-20250423.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T08:11:31.499438+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}